SynthesisMolecular biology reports2026
Ellagic acid and bone health: a systematic review of preclinical studies on its protective role against osteoporosis.
Synthesis in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveOsteoporosis is a prevalent metabolic bone disorder characterized by reduced bone mineral density and disrupted bone microarchitecture, leading to increased fracture risk. Growing interest has focused on natural bioactive compounds as potential complementary therapeutic agents. This systematic review aimed to comprehensively evaluate preclinical evidence regarding the protective effects of ellagic acid (EA), a naturally occurring polyphenolic compound, and to elucidate the molecular mechanisms underlying its role in alleviation of osteoporosis.
methodsA systematic literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar databases up to November 2025, following PRISMA guidelines. Eligible studies included English-language in vivo and in vitro investigations assessing the effects of EA on osteoporosis. Data were extracted on experimental models, EA dosage and administration, evaluated signaling pathways, and bone-related outcomes.
results13 preclinical studies met the inclusion criteria. Evidence consistently demonstrated that EA enhances osteoblast differentiation, viability, and bone-forming capacity by upregulating key osteogenic markers and activating signaling pathways such as SMAD2/3, BMP2, and SIRT1/Nrf2/HO‑1, while inhibiting negative regulators including CDK12. Concurrently, EA markedly suppressed osteoclast differentiation and bone resorption by disrupting RANKL-RANK interactions and inhibiting downstream NF‑κB, MAPK, and ERK signaling pathways. In multiple animal models, including ovariectomy- and microgravity-induced osteoporosis, EA administration improved bone mineral density, trabecular microarchitecture, and mechanical strength. These effects were accompanied by attenuation of oxidative stress and inflammatory responses within the bone microenvironment.
conclusionCollectively, preclinical evidence indicates that EA exerts multifaceted osteoprotective effects by restoring the balance between bone formation and resorption and modulating oxidative and inflammatory pathways. Although these findings support EA as a promising natural candidate for osteoporosis prevention and treatment, large-scale and long-term clinical studies are required to confirm its efficacy, optimize dosing strategies, and address bioavailability challenges.
Indexed as
Identifiers
42700298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.